McFarlane Neil F.
Known title: President and CEOCIK: 0001681098
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.
Transaction History
| ZVRA | ▼ Sell | Open Market | 14,625 | $125K | 2/9/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 37,500 | — | 2/7/2026 | View on chart |
| ZVRA | ▼ Sell | Open Market | 91,000 | $853K | 2/2/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 233,334 | — | 1/31/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 50,000 | — | 10/10/2025 | View on chart |
| ZVRA | ▼ Sell | Open Market | 19,500 | $211K | 10/10/2025 | View on chart |
| ZVRA | ▼ Sell | Open Market | 30,544 | $246K | 2/14/2025 | View on chart |
| ZVRA | ▼ Sell | Open Market | 61,273 | $481K | 2/13/2025 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 233,333 | — | 1/31/2025 | View on chart |
| COLL | ▲ Buy | Grant | 7,693 | $0 | 5/16/2024 | View on chart |
| COLL | ▲ Buy | Grant | 9,792 | $0 | 5/18/2023 | View on chart |
| COLL | ▲ Buy | Grant | 14,035 | $0 | 5/19/2022 | View on chart |
| COLL | ▲ Buy | Grant | 17,845 | $0 | 4/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.